PT-141 and Melanotan II are the two most widely discussed melanocortin peptides in the sexual health and aesthetics space, and they are frequently conflated by people who don't understand the science behind them. That conflation is a serious mistake. These two compounds share a lineage — PT-141 was derived directly from Melanotan II research — but they have diverged dramatically in terms of receptor selectivity, clinical evidence, regulatory status, and safety profile.
One of them is an FDA-approved drug. The other is an unregulated research peptide sold in a gray market with no manufacturing standards, no Phase III trial data, and safety signals that have prompted formal warnings from regulators in the UK, Australia, and the United States. Knowing which is which, and why those distinctions matter clinically, is the entire point of this guide.
This is not a "which is better" comparison in the conventional sense. For most people with a specific sexual health goal and any concern for safety, the decision framework is straightforward. But there are edge cases — particularly around tanning, combined effects, and cost — where understanding the trade-offs in full depth matters. This guide covers all of it.
Quick Comparison
- Generic / brand name: PT-141 is known generically as bremelanotide and sold as Vyleesi; Melanotan II (MT-II) has no approved brand name.
- Molecular formula: PT-141 is C50H68N14O10; Melanotan II is C50H69N15O9.
- Molecular weight: PT-141 is 1,025.16 g/mol; Melanotan II is 1,024.18 g/mol.
- Structure: Both are cyclic heptapeptide analogs of alpha-MSH; PT-141 is a lactam analog.
- Key structural difference: PT-141 carries a hydroxyl group in place of an amide, which reduces MC1R activity; Melanotan II has an amide terminus and broad MC1R–MC5R activity.
- Receptor targets: PT-141 primarily targets MC3R and MC4R with reduced MC1R activity; Melanotan II targets MC1R, MC3R, MC4R, and MC5R.
- Primary effects: PT-141 enhances sexual desire and arousal; Melanotan II produces skin tanning, sexual arousal, and appetite suppression.
- FDA status: PT-141 is approved (Vyleesi, NDA 210557, 2019); Melanotan II is not approved for any indication.
- Clinical trial stage: PT-141 has completed Phase III with long-term extension data; Melanotan II has Phase I data only (Dorr 1996, Wessells 1998).
- Half-life: PT-141 approximately 2.7 hours; Melanotan II approximately 1–2 hours.
- Typical dose (sexual function): PT-141 is 1.75 mg subcutaneous; Melanotan II is 0.25–1 mg subcutaneous.
- Tanning effect: PT-141 produces minimal tanning due to reduced MC1R activity; Melanotan II produces significant tanning as its primary mechanism.
- Nausea incidence: PT-141 approximately 40% based on clinical trial data; Melanotan II produces high nausea especially during the loading phase, though no controlled data exists.
- Melanoma risk: Not documented for PT-141; Melanotan II has case reports in peer-reviewed literature and formal warnings from the MHRA and TGA.
- Priapism risk: Low for PT-141 (not prominently reported in trials); documented for Melanotan II — Wessells 1998 showed dose-dependent erections lasting 1–5 hours.
- WADA status: PT-141 is prohibited (S2; possibly captured under broad language); Melanotan II is prohibited (S2; explicitly named).
- Availability: PT-141 is available by prescription (Vyleesi), through compounding, or as a research chemical; Melanotan II is a research chemical only, not available via prescription.
PT-141: Strengths and Best Uses
PT-141 (bremelanotide) is the most clinically validated melanocortin peptide for sexual dysfunction. Its strengths stem directly from both its engineered receptor selectivity and the rigorous clinical program that brought it to FDA approval.
The Case for PT-141
FDA approval is not a technicality. Vyleesi's 2019 approval was based on two identical Phase III randomized, double-blind, placebo-controlled trials (the RECONNECT program) in 1,267 premenopausal women with acquired, generalized HSDD. Both trials met both coprimary endpoints: statistically significant improvement in sexual desire scores (FSFI-D) and reduction in distress (FSDS-DAO-13, P < 0.001 for both). This is the level of evidence that separates a drug from a research chemical. No comparable data exists for Melanotan II.
Targeted central mechanism. PT-141 concentrates its activity at MC3R and MC4R in the paraventricular nucleus of the hypothalamus. This is precisely where sexual desire and arousal originate neurologically. MC4R knockout animal models abolish the erectogenic response to melanocortin agonists entirely, confirming the receptor's essential role. PT-141 hits this target cleanly, without the MC1R noise that drives Melanotan II's tanning and dermatological risk profile.
Distinct from PDE5 inhibitors. Viagra and Cialis work downstream — they enhance the vascular response to arousal that has already occurred. PT-141 works upstream, at the level of desire and motivation itself. It addresses the neurological deficit in HSDD rather than a mechanical insufficiency in erection. This means it provides benefit in cases where PDE5 inhibitors cannot, including desire-based dysfunction in both sexes and as a combination therapy for men refractory to sildenafil monotherapy. The salvage study by Safarinejad et al. demonstrated that bremelanotide co-administered with sildenafil produced significantly enhanced responses in men who had failed sildenafil alone.
Defined safety profile with prescribing standards. The FDA prescribing information for Vyleesi provides clinicians and patients with precisely characterized cardiovascular effects (peak systolic elevation of ~6 mmHg at 2–4 hours post-dose, returning to baseline within 12 hours), documented contraindications (uncontrolled hypertension, known cardiovascular disease), and management strategies for nausea (ondansetron 30 minutes pre-dose). This safety framework does not exist for Melanotan II.
On-demand dosing without daily commitment. PT-141 requires no daily pill. The approved protocol is 1.75 mg subcutaneous injection at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24-hour period and 8 doses per month. Onset is typically within 30 to 60 minutes and effects persist 6 to 8 hours.
Where PT-141 Falls Short
PT-141 does not tan. For users seeking the combined sexual function and cosmetic tanning effects of Melanotan II, PT-141 simply cannot deliver the pigmentation component — that is a feature of its design, not a deficiency. Nausea remains its most common side effect at approximately 40% of patients, though this typically attenuates after the first dose. Its effects are narrower in scope by design; this is a strength from a safety standpoint but means it will not produce Melanotan II's appetite suppression or the full-body melanin response.
Melanotan II: Strengths and Best Uses
Melanotan II is pharmacologically more active across the melanocortin system than PT-141. That breadth is simultaneously the source of its appeal and the root of its risk.
The Case for Melanotan II
Tanning is the one thing only MT-II can do. PT-141's reduced MC1R activity means it does not produce meaningful melanogenesis. Melanotan II's high-affinity MC1R binding stimulates tyrosinase activity in melanocytes, driving sustained eumelanin production that results in deeper, longer-lasting pigmentation with minimal UV exposure. For users whose primary goal is a tan — with enhanced sexual function as a secondary benefit — this dual profile is unavailable in any FDA-regulated product.
More potent sexual arousal effects in user experience. The Phase I research by Wessells et al. in 1998 documented erections in men with psychogenic erectile dysfunction in a double-blind crossover study using Melanotan II, the work that directly seeded the bremelanotide research program. User reports consistently describe MT-II's sexual arousal effects as more intense and faster-onset than PT-141 at comparable doses — likely a function of its broader receptor engagement and higher binding affinity at MC4R before the structural modifications of PT-141 attenuated that response. No head-to-head clinical trial data exists to quantify this difference.
Appetite suppression is a unique secondary effect. MC3R and MC4R in the hypothalamus regulate feeding behavior and energy balance. MT-II activation at these receptors reduces food intake in animal models, and appetite suppression is a commonly reported effect in human use. PT-141 does not produce this effect in a meaningful way. For users during cutting phases, this secondary effect is a genuine pharmacological bonus, though human body composition trial data remain absent.
Lower cost and longer track record in the research community. MT-II has been available in the gray market for longer than PT-141, is typically cheaper per milligram, and has extensive community-documented protocols despite the absence of formal trial data. For researchers studying melanocortin pharmacology in preclinical models, it remains the reference compound.
Where Melanotan II Falls Short — Decisively
No approved indication. No Phase III data. No regulatory framework. The entire Melanotan II clinical program stopped after Phase I. Dorr et al. 1996 (3 volunteers for tanning) and Wessells et al. 1998 (a small double-blind crossover for erectile dysfunction) constitute the sum total of controlled human research. No large-scale safety or efficacy data exist. This is not a technicality; it means the dose-response, long-term safety, and population-level risk profile of Melanotan II in humans are fundamentally unknown.
Mole darkening and documented melanoma risk. MT-II's potent MC1R stimulation causes existing nevi and freckles to darken rapidly. Multiple published case reports in peer-reviewed dermatology journals have documented melanomas arising during MT-II use. The UK's MHRA and Australia's TGA have issued formal safety warnings citing melanoma risk specifically. The absence of population-level epidemiological data does not make this a theoretical concern; documented case reports in the medical literature mean this is a recognized adverse event class. Individuals with numerous atypical moles, fair skin (Fitzpatrick type I–II), or personal or family history of melanoma face elevated risk.
Priapism is a documented risk in men. The Wessells 1998 study showed dose-dependent erections lasting 1 to 5 hours in subjects receiving MT-II. Priapism — an erection lasting more than 4 hours — is a urological emergency. Delayed treatment can result in permanent erectile dysfunction from ischemic damage to corpus cavernosum tissue. This is not a theoretical risk; it is an event class documented in the original clinical research on the compound.
Head-to-Head: Mechanism
These two peptides share a structural ancestor — alpha-melanocyte-stimulating hormone (alpha-MSH) — and both are cyclic heptapeptide analogs of it. But their receptor engagement profiles have diverged in ways that define everything downstream.
Shared Foundation: The Melanocortin System
Both peptides bind melanocortin receptors and activate cAMP signaling through adenylyl cyclase. Both are resistant to enzymatic degradation due to their constrained cyclic structures. Both reach peak plasma concentrations within 1 to 2 hours of subcutaneous injection and produce onset of effects within 30 to 90 minutes.
The melanocortin receptor family has five subtypes. MC1R sits on melanocytes and mediates pigmentation. MC2R is the ACTH receptor (not relevant here). MC3R and MC4R are expressed densely in hypothalamic nuclei and mediate energy balance, sexual desire, and arousal. MC5R is expressed in exocrine glands and contributes to sebaceous secretion and other peripheral functions.
Where They Diverge
Melanotan II binds MC1R, MC3R, MC4R, and MC5R with broad, potent affinity. This non-selectivity is not accidental — it reflects the original design intent of producing a maximal tanning stimulus. The consequence is that every dose of MT-II activates the entire suite of melanocortin effects simultaneously: melanogenesis through MC1R, appetite suppression through MC3R and MC4R in the arcuate nucleus, sexual arousal through MC4R in the paraventricular nucleus, and exocrine effects through MC5R.
PT-141 is specifically engineered to reduce MC1R activity. The structural modification — substituting a hydroxyl group where MT-II carries an amide — was designed during Palatin Technologies' development program to concentrate therapeutic effects at MC3R and MC4R while stripping out the tanning and dermatological risk that come with strong MC1R agonism. The result is a peptide that hits the sexual function pathway cleanly, with the MC1R-driven tanning and mole-darkening effects dramatically attenuated.
The Hypothalamic Pathway for Sexual Function
Both peptides' sexual effects converge on MC4R in the paraventricular nucleus (PVN) of the hypothalamus. MC4R activation here modulates dopaminergic pathways involved in desire, arousal, and motivation. This upstream mechanism is what separates both peptides from PDE5 inhibitors: rather than enhancing vascular response to stimulation that has already occurred, both MT-II and PT-141 act at the neurological origin of sexual motivation.
MC4R activation in the PVN produces both the motivational component — the "wanting" dimension of desire — and downstream physiological responses including genital blood flow and heightened sensitivity. PT-141's additional activity at MC3R may contribute to the appetitive, motivational dimension of arousal. Melanotan II's broader receptor engagement produces what users describe as more intense and less specific arousal, reflecting the full multi-receptor activation across the hypothalamic landscape.
Which Should You Choose?
The decision framework here is cleaner than most peptide comparisons, because the regulatory gap is so large it functions as a primary filter.
- HSDD in premenopausal women: PT-141. FDA-approved for this exact indication, with prescribing physician oversight and a defined safety profile.
- Male erectile dysfunction / low libido: PT-141 (off-label). Phase IIB trial data exists, and an established protocol with PDE5 inhibitors covers refractory cases.
- Sexual health with physician involvement: PT-141. It is the only option available via prescription or a compounding pharmacy with quality assurance.
- Tanning as the primary goal: Melanotan II. PT-141 does not produce meaningful melanogenesis; MT-II is the only option for this effect.
- Combined tanning and sexual function: Melanotan II. No FDA-approved product produces both effects — proceed with full awareness of the risk profile.
- Appetite suppression: Melanotan II. PT-141 does not produce this effect; MT-II's MC4R activity in the arcuate nucleus is the mechanism.
- Athlete subject to WADA testing: Neither. Both are prohibited; MT-II is explicitly named and PT-141 is likely captured under S2 broad language.
- Personal or family history of melanoma: PT-141 only. Melanotan II's MC1R activation presents unacceptable dermatological risk.
- Atypical or numerous moles: PT-141 only. MT-II-associated mole darkening warrants dermatological monitoring even in low-risk users; the risk is unacceptable here.
- First-time melanocortin peptide user: PT-141. It has a defined dose, an FDA-approved auto-injector format, and well-characterized side effect management.
The bottom line: if your goal is sexual health and you have any meaningful concern for safety, PT-141 is the clear choice. Melanotan II is only defensible for users who specifically want the tanning effect, fully understand that they are operating without a safety net of clinical trial data, and are not in a high-risk category for dermatological adverse events.
Safety Comparison
This is where the gap between these two peptides is most consequential. Understanding it fully is non-negotiable before using either.
PT-141 Safety Profile
PT-141's safety profile is the best characterized of any melanocortin peptide in humans, because it is the only one to have completed Phase III trials. In 1,267 women across two RECONNECT trials:
Nausea was the dominant adverse event, affecting approximately 40% of patients versus 1% on placebo. It typically begins within 30 minutes of injection and lasts about 2 hours. Crucially, it diminishes significantly with subsequent doses — the first dose carries the highest risk. Pre-treatment with ondansetron 30 minutes before injection substantially reduces incidence.
Cardiovascular effects are characterized and mild: a transient systolic blood pressure increase of approximately 6 mmHg peaking at 2 to 4 hours post-dose, with a heart rate reduction of up to 5 beats per minute. Both parameters return to baseline within 12 hours. This well-characterized profile allows clear contraindication management: patients with uncontrolled hypertension or established cardiovascular disease should not use PT-141.
Flushing (20%), injection site reactions (13%), and headache (11%) are common but generally mild and transient.
No melanoma risk from dermatological effect: PT-141's reduced MC1R activity means it does not produce the sustained melanocyte stimulation associated with Melanotan II's mole-darkening risk profile.
Long-term extension data from an open-label follow-up study showed no new safety signals with continued on-demand use beyond the initial 24-week trial.Melanotan II Safety Profile
Melanotan II has no Phase III safety data. Its entire controlled human trial record consists of Phase I studies with a handful of subjects. Every safety statement about MT-II in clinical practice is extrapolated from this thin evidence base plus post-market case reports in the medical literature.
Nausea and flushing are common and often more pronounced than with PT-141, particularly during the loading phase. Community protocols recommend starting at 0.1 mg to assess tolerance. No controlled incidence data exists.
Mole darkening is expected, mechanistically inevitable, and clinically concerning. MT-II's potent MC1R stimulation darkens existing nevi and can produce new ones. Multiple published case reports in dermatology journals have documented melanomas arising during MT-II use. The UK MHRA and Australia's TGA have issued formal consumer warnings about melanoma risk specifically linked to MT-II. The absence of large epidemiological studies establishing population-level causality does not reduce this risk to theoretical — documented case reports in peer-reviewed literature constitute a meaningful safety signal. Anyone using MT-II should have a baseline dermatological assessment and regular monitoring. Any mole showing irregular changes in shape, border, or color during or after MT-II use requires immediate evaluation.
Priapism is a documented risk in men, appearing in the foundational clinical research (Wessells 1998) as dose-dependent erections lasting 1 to 5 hours. Priapism requiring emergency intervention (aspiration or pharmacological reversal) can result in permanent erectile dysfunction if treatment is delayed beyond 4 to 6 hours.
Quality and purity risk is categorically higher for MT-II than for FDA-approved Vyleesi. Products from the gray market vary substantially in purity, potency, and sterility. Contamination with endotoxins, heavy metals, or undeclared compounds is a recognized risk in unregulated peptide markets. There is no manufacturing quality standard applied to MT-II products.
The Regulatory Dimension of Safety
The FDA approval process for Vyleesi required Palatin Technologies to demonstrate not only efficacy but also manufacturing quality, stability data, and a post-market monitoring plan. The prescribing information is a living document updated when new safety information emerges. None of this infrastructure exists for Melanotan II. When you inject MT-II purchased from an online research chemical vendor, you are operating entirely outside any regulatory safety framework.
Dosing and Administration
PT-141 Dosing
The FDA-approved dose is straightforward and fixed:
- 1.75 mg subcutaneous injection, at least 45 minutes before anticipated sexual activity
- Maximum one dose per 24-hour period
- Maximum 8 doses per month
- Injection sites: abdomen (preferred) or anterior thigh
Vyleesi is supplied as a pre-filled single-dose auto-injector requiring no reconstitution. For research-grade PT-141 (lyophilized powder in 10 mg vials), a common reconstitution is 2 mL bacteriostatic water per vial, yielding 5 mg/mL (1.75 mg = 0.35 mL on an insulin syringe). Anti-nausea pre-treatment with ondansetron can be taken 30 minutes before injection.
Off-label dosing in men typically follows the same 1.75 mg subcutaneous protocol, with some clinicians starting lower (0.5–1 mg) to assess tolerability before titrating.
Melanotan II Dosing
No FDA-approved protocol exists. The following is derived from the clinical research literature and community protocols:
Loading phase (tanning goal):
- Start: 0.1 mg to assess tolerance
- Escalate to 0.25 mg daily over 2–4 weeks
- Combine with 10–20 minutes of UV exposure for accelerated pigmentation
Maintenance (after desired pigmentation):
- 0.5–1 mg once or twice weekly
- Continue periodic UV exposure to maintain tan
Sexual function dosing:
- Doses in the 0.25–1 mg range are used for acute sexual function effects, typically administered 30–90 minutes before activity
- The Wessells 1998 study used weight-based dosing (~0.025 mg/kg, approximately 2 mg for an 80 kg individual)
MT-II is supplied as lyophilized powder requiring reconstitution. A common ratio is 10 mL bacteriostatic water per 10 mg vial (1 mg/mL). Evening administration or sleep-through strategy is commonly recommended to reduce nausea severity during the loading phase.
Conclusion
PT-141 and Melanotan II are separated by more than their receptor profiles. They are separated by two decades of clinical development, a Phase III trial program, FDA approval, a defined prescribing framework, and a fundamentally different risk landscape.
PT-141 (bremelanotide) is what you choose when sexual health is the goal and safety matters. The RECONNECT trials delivered statistically significant improvements in both desire scores and distress in over 1,200 women, the cardiovascular effects are characterized and manageable, and nausea — the dominant side effect — diminishes with repeated use. Off-label use in men adds a growing clinical evidence base. This is the only melanocortin peptide you can obtain under physician supervision with manufacturing quality assurances.
Melanotan II is what you choose if and only if tanning or combined tanning-plus-sexual-function effects are specifically what you are after, and you do so with a clear-eyed understanding that you are using an unregulated compound with no Phase III safety data, documented melanoma case reports in the medical literature, a priapism risk in men, and no quality control on the product you are injecting. For users with atypical moles, personal or family melanoma history, fair skin, or any cardiovascular vulnerability, Melanotan II is not a defensible choice under any circumstances.
The historical irony is real: PT-141 exists because Melanotan II worked so well that researchers spent decades trying to extract its best effects into a safer, narrower compound. That refinement succeeded. For the vast majority of users, the result of that scientific effort — Vyleesi — is the correct answer.
For readers exploring other approaches to sexual health and peptide-assisted wellness, see also GHK-Cu, a copper peptide with skin-regenerating and anti-inflammatory properties that supports overall tissue health as a complement to any protocol.